Recent Quotes

My Watchlist

Indicators

Barinthus Biotherapeutics plc - American Depositary Shares (NQ: BRNS )

1.432 -0.058 (-3.89%)

Streaming Delayed Price Updated: 3:01 PM EDT, Nov 1, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	10,864
Open	1.470
Bid (Size)	1.420 (4)
Ask (Size)	1.490 (17)
Prev. Close	1.490
Today's Range	1.430 - 1.510
52wk Range	1.110 - 5.000
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences

October 31, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

October 01, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

Performance

YTD	-61.30%	-61.30%
1 Month	+15.48%	+15.48%
3 Month	+3.02%	+3.02%
6 Month	-35.20%	-35.20%
1 Year	-65.07%	-65.07%

More News

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

September 24, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

Barinthus Biotherapeutics: Q4 Earnings Insights

March 20, 2024

Via Benzinga

BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024

August 08, 2024

Via InvestorPlace

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

August 08, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

August 01, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket

June 21, 2024

Via Benzinga

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

June 12, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

June 06, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

June 05, 2024

Via Benzinga

Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024

May 22, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024

May 13, 2024

Via InvestorPlace

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

May 13, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

May 01, 2024

Via Benzinga

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

May 01, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session

April 30, 2024

Via Benzinga

Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives

April 19, 2024

Via Benzinga

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

April 18, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session

April 04, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session

April 03, 2024

Via Benzinga

BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q4 2023

March 20, 2024

Via InvestorPlace

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

March 20, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session

February 19, 2024

Via Benzinga

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

January 05, 2024

From Barinthus Biotherapeutics

Via GlobeNewswire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.